Individual generic drug information

tranexamic acid

Reference monograph

Part of registered formulation

TRANEXAMIC ACID + MEFENAMIC ACID

Reference record: Tranexamic acid
Source: BNF 80 (2020–2021)
Printed source pages: 139, 140
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Tranexamic acid only.

Indications And Dose

Local fibrinolysis ▶BY MOUTH ▶Adult: 1–1.5 g 2–3 times a day, alternatively 15–25 mg/kg 2–3 times a day ▶INITIALLY BY SLOW INTRAVENOUS INJECTION ▶Adult: 0.5–1 g 2–3 times a day, to be administered at a rate not exceeding 100 mg/minute, followed by (by continuous intravenous infusion) 25–50 mg/kg if required, dose to be given over 24 hours Menorrhagia ▶BY MOUTH ▶Adult: 1 g 3 times a day for up to 4 days, to be initiated when menstruation has started; maximum 4 g per day Hereditary angioedema ▶BY MOUTH ▶Adult: 1–1.5 g 2–3 times a day, for short-term prophylaxis of hereditary angioedema, tranexamic acid is started several days before planned procedures which may trigger an acute attack of hereditary angioedema (e.g. dental work) and continued for 2–5 days afterwards Epistaxis ▶BY MOUTH continued → ▶Adult: 1 g 3 times a day for 7 days General fibrinolysis ▶BY SLOW INTRAVENOUS INJECTION ▶Adult: 1 g every 6–8 hours, alternatively 15 mg/kg every 6–8 hours, dose to be given at a rate not Cardiovascular system exceeding 100 mg/minute Prevention and treatment of significant haemorrhage following trauma ▶INITIALLY BY SLOW INTRAVENOUS INJECTION ▶Adult: Loading dose 1 g to be given over 10 minutes, treatment should commence within 8 hours of injury, followed by (by intravenous infusion) 1 g to be given over 8 hours l UNLICENSED USE Use of tranexamic acid by continuous intravenous infusion for treatment of local ﬁbrinolysis is an unlicensed route of administration. g Not licensed for prevention and treatment of signiﬁcant haemorrhage following trauma. h

Source pages 139, 140

Contra Indications

Fibrinolytic conditions following disseminated intravascular coagulation (unless predominant activation of ﬁbrinolytic system with severe bleeding). history of convulsions. thromboembolic disease

Source page 140

Cautions

Irregular menstrual bleeding (establish cause before initiating therapy). massive haematuria (avoid if risk of ureteric obstruction). patients receiving oral contraceptives (increased risk of thrombosis) CAUTIONS, FURTHER INFORMATION ▶Menorrhagia Before initiating treatment for menorrhagia, exclude structural or histological causes or ﬁbroids causing distortion of uterine cavity.

Source page 140

Safety

Extracted information for Tranexamic acid only.

Interactions

→Appendix 1: tranexamic acid

Source page 140

Side Effects

GENERAL SIDE-EFFECTS ▶Common or very common Diarrhoea (reduce dose). nausea. vomiting ▶Uncommon Allergic dermatitis ▶Rare or very rare Colour vision change (discontinue). embolism and thrombosis ▶Frequency not known Seizure (more common at high doses). visual impairment (discontinue) SPECIFIC SIDE-EFFECTS ▶With intravenous use Hypotension. malaise (on rapid intravenous injection)

Source page 140

Pregnancy

No evidence of teratogenicity in animal studies; manufacturer advises use only if potential beneﬁt outweighs risk—crosses the placenta.

Source page 140

Breast Feeding

Small amount present in milk— antiﬁbrinolytic effect in infant unlikely.

Source page 140

Renal Impairment

Dose adjustments Reduce dose—consult product literature for details.

Source page 140

Monitoring Requirements

Regular liver function tests in long-term treatment of hereditary angioedema.

Source page 140

Dose and formulations

Extracted information for Tranexamic acid only.

Directions For Administration

For intravenous infusion (Cyklokapron ®), give continuously in Glucose 5% or Sodium chloride 0.9%.

Source page 140

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution Tablet ▶Tranexamic acid (Non-proprietary) Tranexamic acid 500 mg Tranexamic acid 500mg tablets | 60 tablet P £32.10 DT = £6.20 ▶Cyklokapron (Mylan) Tranexamic acid 500 mg Cyklokapron 500mg tablets | 60 tablet P £14.30 DT = £6.20 Solution for injection ▶Tranexamic acid (Non-proprietary) Tranexamic acid 100 mg per 1 ml Tranexamic acid 500mg/5ml solution for injection ampoules | 5 ampoule P £7.50 DT = £7.50 (Hospital only) | 10 ampoule P £15.47 DT = £15.47 (Hospital only) ▶Cyklokapron (Pfizer Ltd) Tranexamic acid 100 mg per 1 ml Cyklokapron 500mg/5ml solution for injection ampoules | 10 ampoule P £15.47 DT = £15.47 ANTIHAEMORRHAGICS › HAEMOSTATICS

Source page 140

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

1–1.5 g 2–3 times a day, alternatively

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

0.5–1 g 2–3 times a day, to be administered at a

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

1 g 3 times a day for up to 4 days, to be initiated

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

1–1.5 g 2–3 times a day, for short-term

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

1 g 3 times a day for 7 days

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

1 g every 6–8 hours, alternatively 15 mg/kg

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 140

Adults

First line only; read the complete Indications and dose section above.

Loading dose 1 g to be given over 10 minutes,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 140

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

tranexamic acid

Reference monograph

Part of registered formulation

TRANEXAMIC ACID + MEFENAMIC ACID

Reference record: Tranexamic acid
Source: BNF 80 (2020–2021)
Printed source pages: 139, 140
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Tranexamic acid only.

Indications And Dose

Source pages 139, 140

Contra Indications

Fibrinolytic conditions following disseminated intravascular coagulation (unless predominant activation of ﬁbrinolytic system with severe bleeding). history of convulsions. thromboembolic disease

Source page 140

Cautions

Source page 140

Safety

Extracted information for Tranexamic acid only.

Interactions

→Appendix 1: tranexamic acid

Source page 140

Side Effects

Source page 140

Pregnancy

No evidence of teratogenicity in animal studies; manufacturer advises use only if potential beneﬁt outweighs risk—crosses the placenta.

Source page 140

Breast Feeding

Small amount present in milk— antiﬁbrinolytic effect in infant unlikely.

Source page 140

Renal Impairment

Dose adjustments Reduce dose—consult product literature for details.

Source page 140

Monitoring Requirements

Regular liver function tests in long-term treatment of hereditary angioedema.

Source page 140

Dose and formulations

Extracted information for Tranexamic acid only.

Directions For Administration

For intravenous infusion (Cyklokapron ®), give continuously in Glucose 5% or Sodium chloride 0.9%.

Source page 140

Medicinal Forms

Source page 140

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

1–1.5 g 2–3 times a day, alternatively

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

0.5–1 g 2–3 times a day, to be administered at a

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

1 g 3 times a day for up to 4 days, to be initiated

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

1–1.5 g 2–3 times a day, for short-term

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

1 g 3 times a day for 7 days

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 139

Adults

First line only; read the complete Indications and dose section above.

1 g every 6–8 hours, alternatively 15 mg/kg

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 140

Adults

First line only; read the complete Indications and dose section above.

Loading dose 1 g to be given over 10 minutes,

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 140

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.